Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

DARA BioSciences KRN5500 granted orphan drug designation by FDA for Treatment of Multiple Myeloma


Monday, 16 Jun 2014 07:00am EDT 

DARA BioSciences Inc:Says the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the experimental compound nofollow KRN5 500 for the treatment of multiple myeloma.Earlier KRN5500 received orphan status to be developed for the parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy (CCIPN) that is refractory to conventional analgesics in patients with cancer. 

Company Quote

336.32
-8.2 -2.38%
11:35am EDT